troglitazone has been researched along with Kahler Disease in 4 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone, which has previously been shown to activate AMPK, similarly inhibited MM cell growth, activated AMPK, and decreased ERK and P70S6K phosphorylation." | 1.34 | Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. ( Baumann, P; Emmerich, B; Mandl-Weber, S; Schmidmaier, R; Straka, C, 2007) |
| "Binding of multiple myeloma (MM) cells to bone marrow stromal cells (BMSCs) triggers expression of adhesive molecules and secretion of interleukin-6 (IL-6), promoting MM cell growth, survival, drug resistance, and migration, which highlights the possibility of developing and validating novel anti-MM therapeutic strategies targeting MM cells-host BMSC interactions and their sequelae." | 1.34 | Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. ( Farrar, WL; Wang, LH; Yang, XY; Zhang, X, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kurtoglu, M | 1 |
| Philips, K | 1 |
| Liu, H | 1 |
| Boise, LH | 1 |
| Lampidis, TJ | 1 |
| Wang, LH | 2 |
| Yang, XY | 2 |
| Zhang, X | 2 |
| Huang, J | 1 |
| Hou, J | 1 |
| Li, J | 1 |
| Xiong, H | 1 |
| Mihalic, K | 1 |
| Zhu, H | 1 |
| Xiao, W | 1 |
| Farrar, WL | 2 |
| Baumann, P | 1 |
| Mandl-Weber, S | 1 |
| Emmerich, B | 1 |
| Straka, C | 1 |
| Schmidmaier, R | 1 |
4 other studies available for troglitazone and Kahler Disease
| Article | Year |
|---|---|
High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.
Topics: Antineoplastic Agents; Calcium; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Death; Cell Line, Tu | 2010 |
Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow Cells; Cell Division; Cel | 2004 |
Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Chr | 2007 |
Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP.
Topics: Bone Marrow; CCAAT-Enhancer-Binding Proteins; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Chro | 2007 |